FDA Approves First Gene Therapy for Wiskott-Aldrich Syndrome, Marking Historic Milestone for Non-Profit Drug Development
Key Insights
The FDA has approved Waskyra (search), the first gene therapy for Wiskott-Aldrich syndrome (search) (WAS (search)), a rare genetic immunodeficiency affecting 1 in 250,000 male births.
Fondazione Telethon becomes the first non-profit organization worldwide to receive FDA authorization to distribute a therapy developed from its own research.
Clinical trials demonstrated substantial benefits including a 93% reduction in severe infections and 60% decrease in bleeding events following treatment.
The US Food and Drug Administration has approved Waskyra (search) (etuvetidigene autotemcel (search)), marking the first gene therapy available for patients with Wiskott-Aldrich syndrome (search) (WAS (search)) and establishing a groundbreaking precedent for non-profit drug development. The approval makes Fondazione Telethon ETS the first non-profit organization worldwide to receive FDA authorization to distribute a therapy resulting from its own research and development.
Addressing a Critical Unmet Medical Need
WAS (search) is a rare and life-threatening inherited disease caused by mutations in the WAS gene (search), primarily affecting boys with an estimated incidence of 1 in 250,000 male births. Patients with WAS lack functional WAS protein (search), causing their immune cells and blood cells to develop and function abnormally. This results in severe symptoms including bleeding, eczema, recurrent infections, and increased susceptibility to autoimmune conditions and certain cancers.
"Today's approval addresses the urgent need in the WAS (search) community, where patients have described living 'a life of terrifying worry and fear' without any approved therapies available," commented Vijay Kumar, acting director of the Center for Biologics Evaluation and Research (CBER) Office of Therapeutic Products.
Revolutionary Treatment Approach
Waskyra (search) is an ex vivo gene therapy consisting of a patient's own hematopoietic stem cells (HSCs) that have been genetically modified to include functional copies of the WAS gene (search). The treatment process involves conditioning therapy to suppress the bone marrow, followed by intravenous infusion of the gene-corrected cells, which then engraft to restore blood cell production and immune system function.
The therapy is approved for patients with WAS (search) who are aged six months and older, are healthy enough to tolerate a hematopoietic stem cell transplant (HSCT), and have no matched donor available.
Compelling Clinical Evidence
The safety and effectiveness of Waskyra (search) were demonstrated through two open-label, single-arm clinical trials and an expanded access program involving 27 patients with severe WAS (search). The results showed "substantial and sustained clinical benefit" for patients with severe WAS, according to the FDA.
Key efficacy outcomes included a 93% reduction in severe infections in the six to 18-month period after the one-shot treatment compared to the 12 months before the procedure. Additionally, patients experienced a 60% fall in moderate and severe bleeding events in the first 12 months following treatment.
The most common side effects associated with Waskyra (search) include rash, respiratory tract infection, febrile neutropenia, catheter-related infection, vomiting, diarrhea, liver injury, and petechiae.
Historic Non-Profit Model
The therapy was (search) developed through decades of research at the San Raffaele Telethon Institute for Gene Therapy (search) (SR-Tiget) in Milan. This achievement follows Telethon Foundation (search)'s 2023 milestone when it took responsibility for production and distribution of another gene therapy for Ada-Scid (search) (the disease of "bubble babies") in the European Union.
According to Fondazione Telethon chief executive Ilaria Villa, the approval "confirms the value of a patient-centered model that turns research into real treatments, especially where the market fails to act." This non-profit model provides patients with access to advanced therapies in cases where the pharmaceutical industry withdraws due to inability to see adequate return on investment.
Transformative Impact on Patient Lives
The approval enables patients with WAS (search) to "engage in everyday activities such as going to school or participating in sports," according to Kumar. This represents a significant advancement for a patient population that previously had no approved therapeutic options and faced constant health risks from their compromised immune systems.
The FDA approval follows the positive opinion from the European Medicines Agency (search)'s Committee for Medicinal Products for Human Use (CHMP) for the same therapy, which came several weeks earlier, confirming the global recognition of this treatment's potential.